Company Encyclopedia
View More
name
Taysha Gene Therapies
TSHA.US
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc.
1.946 T
TSHA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking209/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-64.93%E
    • Profit Margin-1583.66%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-36.36%E
    • Net Profit YoY-338.82%E
    • Total Assets YoY75.65%A
    • Net Assets YoY146.62%A
  • Cash ScoreD
    • Cash Flow Margin-6.31%D
    • OCF YoY-36.36%E
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreB
    • Gearing Ratio30.82%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Taysha Gene Therapies Executive Sells Over $1.6 Million in Company Stock

    Reporter NameNagendran SukumarRelationshipPresident and Head of R&D, 10% OwnerTypeSellAmount$1,695,905SEC FilingForm 4Nagendran Sukumar, President and Head of R&D at Taysha Gene Therapies and a 10% owner, sold 370,172 shares of common stock across two transactions on November 28 and December 1, 2025, for a total of $1,695,905. The sales were made at weighted average prices of $4.75 and $4.51 per share, respectively. Following these transactions, Sukumar directly owns 1,006,439 shares of Taysha Gene Therapies.SEC Filing: Taysha Gene Therapies, Inc. [ TSHA ] - Form 4 - Dec. 01, 2025

    TradingView·
    US
    TSHA
    +12.69%
    TradingView·
    US
    TSHA
    +12.69%

    Pres Nagendran Files To Sell 370,172 Of Taysha Gene Therapies Inc [TSHA]

    Nagendran Sukumar, President of Taysha Gene Therapies Inc, filed a Form 144 with the SEC to sell 370,172 shares of restricted stock on November 28, 2025. The sale will be conducted through Jefferies LLC. Filing Form 144 is a requirement before selling restricted securities, allowing the sale within 90 days of filing.

    Reuters·
    US
    TSHA
    +12.69%
    Reuters·
    US
    TSHA
    +12.69%

    Mitsubishi UFJ Asset Management Co. Ltd. Buys New Stake in Taysha Gene Therapies, Inc. $TSHA

    Mitsubishi UFJ Asset Management Co. Ltd. acquired 80,571 shares of Taysha Gene Therapies, Inc. in the second quarter, valued at approximately $186,000. This purchase is part of a broader trend of institutional investors modifying their holdings in the company. Taysha Gene Therapies focuses on developing gene therapies for central nervous system diseases. The company's stock has been rated as a "Moderate Buy" by analysts, with a target price of $10.30.

    Market Beat·
    US
    TSHA
    +12.69%
    Market Beat·
    US
    TSHA
    +12.69%

    Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 8.5% - Here's What Happened

    Taysha Gene Therapies (NASDAQ:TSHA) shares fell 8.5% to $3.9050, with trading volume down 34% from average levels. Analysts have set new price targets, with JMP Securities and Citizens Jmp raising their targets to $8.00, while Needham & Company maintains a $10.00 target. The company reported a quarterly EPS of ($0.09) and revenue of $1.90 million, meeting estimates. Insider Sukumar Nagendran sold 200,000 shares, reducing ownership by 16.58%. Institutional investors hold 77.70% of the stock, which focuses on gene therapies for central nervous system diseases.

    Market Beat·
    US
    TSHA
    +12.69%
    Market Beat·
    US
    TSHA
    +12.69%

    Taysha Gene Therapies (TSHA) Receives a Rating Update from a Top Analyst

    Taysha Gene Therapies (TSHA) has received a Strong Buy consensus rating from analysts, with an average price target of $10.27, indicating a potential upside of 140.52%. Analyst Lee, who covers the Healthcare sector, has a notable average return of 31.4% and a success rate of 57.47% on stock recommendations. Citizens JMP also maintains a Buy rating with a price target of $8.00.

    Tip Ranks·
    US
    TSHA
    +12.69%
    Tip Ranks·
    US
    TSHA
    +12.69%
    © 2025 Longbridge｜Disclaimer